Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-101 in advanced solid tumors with PTCH1 mutations
NCT05199584Phase 2Completed
- Sponsor
- Endeavor BioMedicines
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of taladegib in solid tumor, sponsored by Endeavor BioMedicines. Started May 2022; status: completed.
02
Drugs
taladegib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05199584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199584.